New hope for Hard-to-Treat cancers: targeted drug enters human testing
NCT ID NCT05533463
First seen Nov 01, 2025 · Last updated May 10, 2026 · Updated 31 times
Summary
This early-stage study tests a new drug called HRS-4642 in about 100 adults with advanced solid tumors that have a specific KRAS G12D mutation. The main goal is to check the drug's safety and find the best dose. Researchers will also look for early signs that the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
Conditions
Explore the condition pages connected to this study.